NCT04430842: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

NCT04430842
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: 

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least 1 measurable lesion that has not been previously irradiated
Exclusions: Patients with active, uncontrolled, or symptomatic leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04430842

Comments are closed.

Up ↑